160
Views
1
CrossRef citations to date
0
Altmetric
Commentary

Antisense Oligonucleotide Drugs for Duchenne Muscular Dystrophy: How Far Have We Come and What Does the Future Hold?

&
Pages 1631-1635 | Published online: 01 Oct 2015
 

Financial & competing interests disclosure

This work was supported by grants from the Canadian Institutes of Health Research, University of Alberta Faculty of Medicine and Dentistry, The Friends of Garrett Cumming Research Fund, HM Toupin Neurological Science Research Fund, Muscular Dystrophy Canada, Canada Foundation for Innovation (CFI), Alberta Advanced Education and Technology, and the Women and Children's Health Research Institute (WCHRI). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript.

No writing assistance was used in the production of this manuscript.

Additional information

Funding

This work was supported by grants from the Canadian Institutes of Health Research, University of Alberta Faculty of Medicine and Dentistry, The Friends of Garrett Cumming Research Fund, HM Toupin Neurological Science Research Fund, Muscular Dystrophy Canada, Canada Foundation for Innovation (CFI), Alberta Advanced Education and Technology, and the Women and Children's Health Research Institute (WCHRI). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.